Novel Intravaginal Ring as a Non-Hormonal Contraceptive Multipurpose Prevention Technology (MPT)

The Population Council and partners are advancing the development of a non-hormonal vaginal ring with potential to provide contraception along with broad microbial action against bacterial vaginosis-associated bacteria, HIV, HSV-2, chlamydia, and gonorrhea. This ring will also be designed with the added benefit of promoting vaginal health by helping to maintain optimal vaginal pH and reducing symptoms of bacterial vaginosis.

Dual Prevention Pill (DPP) / TELE

The proposed product is a fixed-dose combination (FDC) tablet of TDF / FTC / LNG / EE indicated for both the prevention of HIV and pregnancy.  The product will be supplied as a 28-count blister compliance pack containing 21 tablets of the fixed-dose combination of TDF, FTC, LNG, and EE (a 3-week supply) plus 7 tablets of FTC and TDF (a 1-week supply).

Ultra-Long-Acting MPT In-situ Forming Implant (ISFI)

First-in-line, ultra-long-acting injectable MPT that offers durable and sustained protection from HIV transmission, high efficacy of contraception, increased user compliance, and the ability to be removed. It consists of a liquid MPT formulation utilizing excipients that form a biodegradable depot after subcutaneous injection (in-situ forming implant (ISFI)).

Dual Prevention Pill (DPP) Regimen

An investigational 28-day contraceptive pill regimen that also provides protection against HIV. 21 pills will contain Emtricitabine and Tenofovir Alafenamide and EE/LNG; 7 pills will contain Emtricitabine and Tenofovir Alafenamide only.

Dapivirine + Pritelivir + Levonorgestrel 3D Printed IVR

Our paramount innovation is use of digital light synthesis – a novel 3D printing process known as continuous liquid interface production (CLIP™) – for rapid, scalable, and cost-effective manufacturing of geometrically and mechanically tunable, rationally designed intravaginal rings as platforms for multi-drug delivery.

Copper Intravaginal Ring (Cu-IVR)

Development of prototypes of long- and short-acting versions of an innovative female-controlled, non-hormonal copper vaginal contraceptive method that may also reduce risk for acquisition of sexually transmitted infections and will be suitable for Phase I human clinical testing.

Novel mAb contraceptive + TDF IVR

Formulation of a novel, nonhormonal contraceptive agent based on a multivalent monoclonal antibody (mAb) that blocks sperm from swimming through mucus and accessing the egg with antiretroviral (ARV) agents with demonstrated clinical efficacy in preventing HIV in a behavior-monitoring IVR.